Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: Updated results of a multi-center, single-arm, phase 2 trial

被引：0
|
作者：
Zhao, Wensi
Li, Jun
Li, Liping
Huang, Junping
Gong, Wei
Yu, Xiongjie
Le, Kefa
He, Linli
Han, Qi
Wang, Songlin
Tang, Ze
Li, Wenbin
Hua, Xianliang
Chen, Yongshun
机构：
[1] Wuhan Univ, Renmin Hosp, Wuhan, Peoples R China
[2] Cent Hosp Xiao Gan, Dept Oncol, Xiaogan, Peoples R China
[3] Xiantao First Peoples Hosp, Xiantao, Peoples R China
[4] Jianghan Oilfield Gen Hosp, Qianjiang, Peoples R China
[5] Hubei Univ Art & Sci, Dept Oncol, Xiang Yang Cent Hosp, Xiangyang, Peoples R China
[6] Peoples Hosp Shiyan, Shiyan, Peoples R China
[7] Peoples Hosp Yangxin, Dept Oncol, Yangxin, Peoples R China
[8] First Peoples Hosp Tianmen City, Hubei Technol Coll, Dept Abdominal & Pelv Med Oncol, Affiliated Hosp, Tianmen, Peoples R China
[9] Xianning Cent Hosp, Xianning, Peoples R China
[10] Zhongxiang Peoples Hosp, Zhongxiang, Peoples R China
[11] Huangshi Cent Hosp, Dept Oncol, Huangshi, Hubei, Peoples R China
[12] Qianjiang Cent Hosp, Dept Oncol, Qianjiang, Peoples R China
[13] Wuhan Univ, Dept Clin Oncol, Renmin Hosp, Wuhan, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
基金：
中国国家自然科学基金;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3571
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: A multicenter, single-arm phase 2 trial
    Zhao, Wensi
    Li, Liping
    Huang, Junping
    Li, Jun
    Gong, Wei
    He, Lilin
    Chen, Yuan
    Wang, Songlin
    Yu, Xiongjie
    Han, Qi
    Ke, Shaobo
    Shi, Wei
    Chen, Yongshun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] An Open-label, Single-arm, Phase 2 Trial of Panitumumab Plus FOLFIRI as Second-line Therapy in Patients with Metastatic Colorectal Cancer
    Cohn, Allen L.
    Shumaker, Grace C.
    Khandelwal, Pankaj
    Smith, David A.
    Neubauer, Marcus A.
    Mehta, Nilesh
    Richards, Donald
    Watkins, David L.
    Zhang, Kathy
    Yassine, Mohamed R.
    CLINICAL COLORECTAL CANCER, 2011, 10 (03) : 171 - 177
  • [3] Liposomal irinotecan+5-fluorouracil plus leucovorin plus bevacizumab as second-line therapy in metastatic colorectal cancer (IRIS): A multi-center, single-arm, prospective, phase II study.
    Hu, Xuhua
    Jiang, Bo
    Hongxia, Lu
    Yu, Bin
    Yi, Bo
    Wang, Yudong
    Zhu, Lingjun
    Li, Shengmian
    Li, Baokun
    Kong, Dalu
    Wang, Zhiwu
    Niu, Wenbo
    Ma, Hongqing
    Wang, Shanchuan
    Chen, Yanglin
    Lin, Chao
    Yang, Rong
    Zhu, Weiyou
    Liu, Jia
    Wang, Guiying
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 195 - 195
  • [4] Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer: A multi-center, open-label, single-arm, phase II study
    Peng, Peijian
    Xu, Xiaolu
    Zhong, Jincai
    Lin, Hong
    Wang, Hong
    Ye, Jin-Hui
    Du, Caiwen
    Wang, Zhi-Hui
    Yu, Gengsheng
    Zou, Guorong
    Ouyang, Jie
    Wang, Yong-Xia
    Li, Lu-Zhen
    Xu, Fei
    Cui, Shi-En
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multi-center, phase II study
    Cheng, Yu
    Teng, Zan
    Zhang, Yanqiao
    Jin, Bo
    Zheng, Zhendong
    Man, Li
    Wang, Zhenghua
    Teng, Yuee
    Yu, Ping
    Shi, Jing
    Luo, Ying
    Wang, Ying
    Zhang, Jingdong
    Zhang, Huijuan
    Liu, Jiwei
    Chen, Hao
    Xiao, Jiawen
    Zhao, Lei
    Zhang, Lingyun
    Jiang, Yu
    Chen, Ying
    Zhang, Jian
    Wang, Chang
    Liu, Sa
    Qu, Jinglei
    Qu, Xiujuan
    Liu, Yunpeng
    BMC CANCER, 2024, 24 (01)
  • [6] Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multi-center, open-label, single-arm, phase II study
    Peng, PeiJian
    Xu, Xiao-Lu
    Zhong, Jin-Cai
    Ye, Jin-Hui
    Wang, Zhi-Hui
    Wang, Hong
    Lin, Hong
    Du, Cai-Wen
    Zou, Guorong
    Ouyang, Jie
    Shi, Ying-Ying
    Xu, Fei
    Yu, Geng-Sheng
    Lu, Yong-Kui
    Wang, Yong-Xia
    Cui, Shi-En
    Li, Lu-Zhen
    CANCER RESEARCH, 2024, 84 (09)
  • [7] Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial
    Ahn, Daniel H.
    Ridinger, Maya
    Cannon, Timothy L.
    Mendelsohn, Lawrence
    Starr, Jason S.
    Hubbard, Joleen M.
    Kasi, Anup
    Barzi, Afsaneh
    Samuelsz, Errin
    Karki, Anju
    Subramanian, Ramanand A.
    Yemane, Divora
    Kim, Roy
    Wu, Chu-Chiao
    Croucher, Peter J. P.
    Smeal, Tod
    Kabbinavar, Fairooz F.
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (07)
  • [8] Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study
    Ma, Shoucheng
    Chen, Rui
    Duan, Ling
    Li, Chunmei
    Yang, Tianning
    Wang, Jiankai
    Zhao, Da
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (02) : 1052 - 1063
  • [9] The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)
    Nakayama, Goro
    Ishigure, Kiyoshi
    Yokoyama, Hiroyuki
    Uehara, Keisuke
    Kojima, Hiroshi
    Ishiyama, Akiharu
    Hayashi, Naomi
    Takano, Nao
    Hattori, Norifumi
    Kobayashi, Daisuke
    Tanaka, Chie
    Hayashi, Masamichi
    Kanda, Mitsuro
    Yamada, Suguru
    Sugimoto, Hiroyuki
    Koike, Masahiko
    Fujiwara, Michitaka
    Fujii, Tsutomu
    Murotani, Kenta
    Ando, Yuichi
    Kodera, Yasuhiro
    BMC CANCER, 2017, 17
  • [10] The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)
    Goro Nakayama
    Kiyoshi Ishigure
    Hiroyuki Yokoyama
    Keisuke Uehara
    Hiroshi Kojima
    Akiharu Ishiyama
    Naomi Hayashi
    Nao Takano
    Norifumi Hattori
    Daisuke Kobayashi
    Chie Tanaka
    Masamichi Hayashi
    Mitsuro Kanda
    Suguru Yamada
    Hiroyuki Sugimoto
    Masahiko Koike
    Michitaka Fujiwara
    Tsutomu Fujii
    Kenta Murotani
    Yuichi Ando
    Yasuhiro Kodera
    BMC Cancer, 17
12345